Selank administration normalizes pro-inflammatory cytokine levels in rats subjected to 20 days of 'social' stress
Background
It was once believed that inflammation and direct immune responses were the sole triggers for the production of key cytokines like interleukin-1β (IL-1β) and interleukin-6 (IL-6). However, recent data indicates that significant psychological or social stress can also be a potent stimulus, enhancing the production of these pro-inflammatory molecules. This stress-induced cytokine release can alter the functional activity of immunocompetent cells, potentially leading to inflammation, or directly impact neuronal function. This creates a need for interventions that can mitigate the immunological consequences of chronic stress. Selank, a glyprolin neuropeptide, is being investigated for its potential stress-protective activities, specifically its ability to modulate this neuro-immune axis under stressful conditions.
Study Design
The study used white nonlinear male rats to model 'social' stress. Animals were paired in cages divided by a septum that allowed sensory contact but prevented physical interaction. Daily, the septum was removed for 10 minutes, leading to agonistic confrontations. The experiment lasted 20 days and involved three groups: an intact control group, a group subjected to the stress protocol, and a stressed group that received Selank at a dose of 100 mcg/kg/day via intraperitoneal injection. The primary endpoint was the level of various cytokines in the blood serum, which was measured using an enzyme-linked immunosorbent assay (ELISA).
Results
The 'social' stress protocol led to a statistically significant increase in the serum concentration of pro-inflammatory cytokines IL-1β and IL-6, as well as the regulatory cytokine TGF-β1, in the stressed control group compared to intact animals. While there was a trend towards decreased IL-4 and increased TNF-α, these changes were not statistically significant in the stressed-only group. The administration of Selank under these stressful conditions demonstrated a significant therapeutic effect.
The neuropeptide caused a decrease in the concentration of IL-1β and IL-6, restored the level of IL-4, and suppressed the production of both TGF-β1 and TNF-α. Critically, Selank treatment reduced the levels of IL-1β, IL-6, TNF-α, and TGF-β1 to values that were practically equivalent to those of the non-stressed control group, indicating a powerful normalizing effect on the stress-induced immune dysregulation.
Key Findings
- 20 days of 'social' stress caused a statistically significant increase in serum IL-1β, IL-6, and TGF-β1 in rats.
- Selank (100 mcg/kg/day, IP) significantly decreased the stress-induced elevation of IL-1β and IL-6.
- Selank administration suppressed the production of TGF-β1 and TNF-α in stressed animals.
- The peptide restored the levels of the anti-inflammatory cytokine IL-4, which had trended downwards with stress.
- Post-Selank treatment, the levels of IL-1β, IL-6, TNF-α, and TGF-β1 returned to values near those of the non-stressed control group.
Why It Matters
This study suggests that Selank may function as a potent immunomodulatory agent, specifically by counteracting the inflammatory cascade triggered by chronic psychological stress. For individuals using peptides to manage stress or anxiety, this provides a potential mechanism of action beyond purely neurological effects, linking Selank to the regulation of the neuro-immune system. Selank could be a valuable tool for mitigating the low-grade systemic inflammation that is often a consequence of chronic stress. This animal model provides a strong rationale for further investigation into the role of cytokines in stress-induced pathologies and highlights Selank as a candidate for developing optimal correction strategies. Before human application, further studies are needed to confirm these effects and establish safe and effective protocols, but the findings position Selank as a promising stress-protective compound with clear anti-inflammatory properties.
TitrateLab articles covering Selank
Written by TitrateLab, separately from the study summarized above.
